Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thomas Farge"'
Autor:
Jean-Emmanuel Sarry, Thomas Farge, Eléonore Kaphan, Emeline Boet, Francois Vergez, Marie Sabatier, Jérôme Kluza, Nathalie Nicot, Yujue Wang, Andrew H. Wei, Aurélie Bousard, Noémie Gadaud, Pierre-Luc Mouchel, Ambrine Sahal, Nesrine Aroua, Ing Soo Tiong, Nathaniel Polley, Lucille Stuani, Mathilde Gotanègre, Quentin Fovez, Tony Kaoma, Laura Poillet-Perez, Claudie Bosc, Estelle Saland, Marie Tosolini, Guillaume Cognet, Rafael J. Argüello, Florian Rambow, Jean-Jacques Fournié, Christian Recher, Carine Joffre, Clément Larrue, Xiaoyang Su, Jean-Christophe Marine, Jerome Tamburini, Céline Mazzotti, Muriel Picard, Hervé Avet-Loiseau, Florence Cabon, Latifa Jarrou
Publikováno v:
Nature Cancer
Nature Cancer, 2021, 2 (11), pp.1204-1223. ⟨10.1038/s43018-021-00264-y⟩
Nature Cancer, 2021, 2 (11), pp.1204-1223. ⟨10.1038/s43018-021-00264-y⟩
Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML). Here we define a ‘MitoScore’ signature, which identifies high mitochondrial oxidative phosphorylation in vivo and in patients with AML. Primary AML cells wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b53df2ce4295c18f2bfd97c1ac0618
https://amu.hal.science/hal-03565962
https://amu.hal.science/hal-03565962
Autor:
Thomas Farge, Marie-Virginie Larcher, Françoise Huguet, Estelle Saland, Suzanne Tavitian, Emilie Bérard, Audrey Sarry, Mauricette Michallet, François Vergez, Sarah Bertoli, Claudie Bosc, Etienne Paubelle, Jean-Emmanuel Sarry, Eric Delabesse, Xavier Thomas, Christian Recher, Clément Larrue
Publikováno v:
European Journal of Haematology. 102:131-142
Objectives We previously reported the prognostic value of serum ferritin in younger patients with intermediate-risk acute myeloid leukemia (AML). The aims of this study were to confirm this finding in a larger cohort regardless of age and prognostic
Autor:
Margherita Ghisi, Jerome Tamburini, Marie Sabatier, Massimiliano Bardotti, Francisco Azuaje, Jean-Charles Portais, Christian Récher, Carine Joffre, Lucille Stuani, Pierre-Luc Mouchel, Camille Laurent, Marie-Laure Nicolau-Travers, Fetta Mazed, Claudie Bosc, Nathalie Nicot, Nesrine Aroua, Mathilde Gotanègre, Jean-Emmanuel Sarry, Estelle Saland, Clément Larrue, Floriant Bellvert, Fabienne De Toni, Latifa Jarrou, Mohsen Hosseini, Charlotte Syrykh, Ryan Gwilliam, François Vergez, Tony Kaoma, Sarah Gandarillas, Muriel Picard, Thomas Farge, Emeline Boet, Nathalie Bonnefoy
Publikováno v:
Cancer Discovery
Cancer Discovery, 2020, 10 (10), pp.1544-1565. ⟨10.1158/2159-8290.CD-19-1008⟩
Cancer Discovery, American Association for Cancer Research, 2020, 10 (10), pp.1544-1565. ⟨10.1158/2159-8290.CD-19-1008⟩
Cancer Discovery, 2020, 10 (10), pp.1544-1565. ⟨10.1158/2159-8290.CD-19-1008⟩
Cancer Discovery, American Association for Cancer Research, 2020, 10 (10), pp.1544-1565. ⟨10.1158/2159-8290.CD-19-1008⟩
Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine-resistant leukemic cells fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12d1d987207bbabb0832871f8ebdd298
https://hal.inrae.fr/hal-02983257
https://hal.inrae.fr/hal-02983257
Autor:
Quentin Heydt, Jean-Emmanuel Sarry, Nizar Serhan, Jan-Henrik Mikesch, Thomas Farge, Ambrine Sahal, Christian Récher, Clément Larrue, Christoph Schliemann, Marie Sabatier, Nesrine Aroua, Nathan Guiraud, Sarah Mouche, Emeline Boet, Marine Dubois, Lucille Stuani, Jerome Tamburini, François Vergez, Pierre-Luc Mouchel, Estelle Saland, Mathilde Gotanègre, Tony Kaoma, Claudie Bosc, Linus Angenendt, Marie-Laure Nicolau-Travers
Drug tolerant leukemic cell subpopulations may explain frequent relapses in acute myeloid leukemia (AML), suggesting that these Relapse-Initiating Cells (RICs) persistent after chemotherapy represent bona fide targets to prevent drug resistance and r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c8ff8a5a00de4d688494fb1e4c05ba0
https://doi.org/10.1101/2020.08.17.253542
https://doi.org/10.1101/2020.08.17.253542
Autor:
Francisco Azuale, Margherita Ghisi, Fetta Mazed, Claudie Bosc, Marie-Laure Nicolau-Travers, François Vergez, Thomas Farge, Mathilde Gotanègre, Jean-Emmanuel Sarry, Jerome Tamburini, Nesrine Aroua, Clément Larrue, Jean-Charles Portais, Floriant Bellvert, Pierre-Luc Mouchel, Christian Récher, Massimiliano Bardotti, Fabienne De Toni, Camille Laurent, Emeline Boet, Marie Sabatier, Lucille Stuani, Nathalie Bonnefoy, Charlotte Syrykh, Ryan Gwilliam, Tony Kaoma, Latifa Jarrou, Sarah Gandarillas, Estelle Saland, Nathalie Nicot, Mohsen Hosseini
Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734aa9774011a29c2e944b92244111d5
https://doi.org/10.1101/806992
https://doi.org/10.1101/806992
Autor:
Claudie Bosc, Jean-Emmanuel Sarry, Marc Piechaczyk, Thomas Farge, Sonia Zaghdoudi, Mohsen Hosseini, Hamid Reza Rezvani, Véronique Guyonnet-Duperat, Clément Larrue, Mathilde Gotanègre, Nesrine Aroua, Pierre Luc Mouchel, Latifa Jarrou, Marie Sabatier, Christian Recher, Guillaume Bossis, Estelle Saland
Publikováno v:
Cancer Research
Cancer Research, American Association for Cancer Research, 2019, 79 (20), pp.5191-5203. ⟨10.1158/0008-5472.CAN-19-0515⟩
Cancer Research, American Association for Cancer Research, 2019, 79 (20), pp.5191-5203. ⟨10.1158/0008-5472.CAN-19-0515⟩
Chemotherapies alter cellular redox balance and reactive oxygen species (ROS) content. Recent studies have reported that chemoresistant cells have an increased oxidative state in hematologic malignancies. In this study, we demonstrated that chemoresi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc41bc9f60c1650a8b74e7e7404e62da
https://hal.umontpellier.fr/hal-02394533
https://hal.umontpellier.fr/hal-02394533
Autor:
François Vergez, Marine Fraisse, Nicolas Broin, Thomas Farge, Robin L. Perry, Jean-Emmanuel Sarry, Audrey Sarry, Suzanne Tavitian, Stéphanie Cassant-Sourdy, Mayumi Sugita, Laetitia K. Linares, Jason S. Iacovoni, Claudie Bosc, Olivier Duchamp, Gwenn Danet-Desnoyers, Fabienne De Toni, Sarah J. Scotland, Y Barreira, Pierre Hirsch, Emmanuel Griessinger, Estelle Saland, Camille Montersino, Rémy Castellano, Héléna Boutzen, Nizar Serhan, Laurent Vallar, Martin Carroll, Christian Recher, Moshen Hosseini, Yves Collette, Lara Gales, François Delhommeau, Marion David, Marie-Laure Nicolau-Travers, Jean-Charles Portais, Nesrine Aroua, Lucille Stuani, Clément Larrue, Tony Kaoma, Tony Lionel Palama, Mary A. Selak, Barbara Garmy-Susini, Virginie Féliu
Publikováno v:
Cancer Discovery
Cancer Discovery, American Association for Cancer Research, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.cd-16-0441⟩
Cancer Discovery, American Association for Cancer Research, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.CD-16-0441⟩
Cancer Discovery, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.cd-16-0441⟩
Cancer Discovery, American Association for Cancer Research, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.cd-16-0441⟩
Cancer Discovery, American Association for Cancer Research, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.CD-16-0441⟩
Cancer Discovery, 2017, 7 (7), pp.716-735. ⟨10.1158/2159-8290.cd-16-0441⟩
Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC). To validate this hypothesis in vivo, we developed a clinically relevant chemotherapeutic approach treating pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c6cd90750845fe1c10175feb49744a
https://hal.archives-ouvertes.fr/hal-01608532
https://hal.archives-ouvertes.fr/hal-01608532
Autor:
Thomas Farge
Publikováno v:
Clinical Cancer Research. 22:B06-B06
The major therapeutic barrier in acute myeloid leukemia (AML) is chemotherapy resistance. AML cells resistant to conventional chemotherapy targeting DNA synthesis are thought to be enriched in quiescent leukemic stem cells (LSCs). In order to better